Benitec Biopharma Inc. (BNTC) has drawn renewed attention following a series of clinical and regulatory developments tied to its gene therapy pipeline. With recent designations from global health authorities and early signs of clinical activity, the company's progress has positioned it as one to monitor in the evolving genetic medicine space.
BB-301 Shows 100% Response Rate
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com